- NCIt
- C2960
Loading cancer entity…
Loading cancer entity…
Clinical trials
67 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04635423 | Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064) | completed | Phase 3 | 1,059 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT02750202 | Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts(TheraVACCS) | completed | Phase 3 | 52 | University of PretoriaOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT00092534 | Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)(FUTURE II) | completed | Phase 3 | 12,167 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 1, 2025 | clinicaltrials |
| NCT05372016 |
Data updated 22 days agoSource updated Jun 11, 2026source: clinicaltrials
| Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females |
| completed |
| Phase 3 |
| 1,200 |
| Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY |
| 1 |
| Nov 24, 2023 |
| clinicaltrials |
| NCT04425291 | Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,680 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 25, 2022 | clinicaltrials |
| NCT03158220 | Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) | completed | Phase 3 | 1,212 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Nov 21, 2019 | clinicaltrials |
| NCT00543543 | Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) | completed | Phase 3 | 14,840 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT01047345 | A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) | completed | Phase 3 | 924 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT01651949 | Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) | completed | Phase 3 | 2,520 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT00092482 | Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) | completed | Phase 3 | 3,882 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 22, 2017 | clinicaltrials |
| NCT00517309 | Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)(FUTURE) | completed | Phase 3 | 1,877 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 22, 2017 | clinicaltrials |
| NCT00092521 | Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) | completed | Phase 3 | 5,759 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 25, 2015 | clinicaltrials |
| NCT00501137 | A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine(BCGov-01) | completed | Phase 3 | 830 | Simon DobsonOTHER | 1 | Apr 10, 2015 | clinicaltrials |
| NCT00092495 | Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) | completed | Phase 3 | 3,055 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 13, 2015 | clinicaltrials |
| NCT00735462 | Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts | completed | Phase 3 | 511 | Graceway Pharmaceuticals, LLCINDUSTRY | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00674739 | Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts | completed | Phase 3 | 470 | Graceway Pharmaceuticals, LLCINDUSTRY | 1 | May 24, 2011 | clinicaltrials |
| NCT00999986 | Low Dose Cyclophosphamide Treats Genital Warts | completed | Phase 3 | 104 | Huazhong University of Science and TechnologyOTHER | 1 | Nov 25, 2009 | clinicaltrials |